Lung cancer is one of the most common cancers in the world. Conventional chemotherapy can prolong the survival of lung cancer patients, but the results are still not ideal. With the improvement of gene detection technology, targeted therapy and immunotherapy have significantly prolonged the survival of patients with lung cancer, but a proportion of patients did not benefit from it. Antibody-drug conjugate (ADC) is a kind of antitumor drug with a unique mechanism of action, containing highly specific and affinity antibodies, sufficiently cytotoxic payloads and highly stable linkers, which couple the powerful cancer-killing impact of traditional chemotherapy drugs with the precision of the antibody. Recently, many ADCs targeting lung cancer are undergoing basic research and clinical trials. In this article, we mainly reviewed the recent development of ADCs in the treatment of lung cancer.